2021
Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseProspective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinEthiodized OilHumansLiver NeoplasmsProspective StudiesTreatment OutcomeConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastases
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastasesClinical Experience with Real-Time 3-D Guidance Based on C-Arm-Acquired Cone-Beam CT (CBCT) in Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Placement
Böning G, Lüdemann WM, Chapiro J, Jonczyk M, Hamm B, Günther RW, Gebauer B, Streitparth F. Clinical Experience with Real-Time 3-D Guidance Based on C-Arm-Acquired Cone-Beam CT (CBCT) in Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Placement. CardioVascular And Interventional Radiology 2018, 41: 1035-1042. PMID: 29541837, DOI: 10.1007/s00270-018-1877-4.Peer-Reviewed Original ResearchMeSH KeywordsCone-Beam Computed TomographyFeasibility StudiesFemaleFluoroscopyHepatic VeinsHumansHypertension, PortalImaging, Three-DimensionalMaleMiddle AgedPortal VeinPortasystemic Shunt, Transjugular IntrahepaticProspective StudiesPuncturesRadiography, InterventionalRetrospective StudiesStentsTreatment OutcomeUltrasonographyConceptsPuncture attemptsTIPSS placementTIPSS procedureProcedure timeTransjugular intrahepatic portosystemic stent shunt placementMean puncture timeSuccess ratePortal vein punctureSignificant differencesShunt placementPuncture timeConsecutive casesMedian numberProspective groupVein punctureUS guidanceClinical experienceControl groupCone beamStudy designCone-beam CTMean timeDoseCBCT guidancePatients
2015
A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization
Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. European Radiology 2015, 25: 3255-3262. PMID: 25956933, PMCID: PMC4595540, DOI: 10.1007/s00330-015-3717-0.Peer-Reviewed Original ResearchConceptsDose area productDigital subtraction angiographyTransarterial chemoembolizationCone-beam CTRadiation exposureLiver cancerDSA image qualityCumulative dose area productSecondary liver cancerLiver cancer patientsTwo-arm trialSignificant differencesResultsBoth cohortsDiagnostic image qualityPatient characteristicsConsecutive patientsTumor burdenTACE proceduresCancer patientsSubtraction angiographyPatientsHIPAA compliantDigital fluoroscopyProcedure courseIndependent readersHow I Do It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting
Lee H, Chapiro J, Schernthaner R, Duran R, Wang Z, Gorodetski B, Geschwind JF, Lin M. How I Do It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting. Academic Radiology 2015, 22: 527-533. PMID: 25641319, PMCID: PMC4355209, DOI: 10.1016/j.acra.2014.12.002.Peer-Reviewed Original ResearchConceptsDatabase management systemDatabase systemsManagement systemUser interface systemData storage problemCustom searchRetrieval criteriaInterface systemData inputAutomatic calculationStorage problemData collectionStorage systemDatabaseRetrievingStoringSystemWorkflowRobust toolBoard-certified radiologists